Several glycolytic enzymes, including phosphofructokinase, pyruvate kinase, and hexokinase, as well as members of the glucose transporter (GLUT) and Na+/glucose co-transporter (SGLT) families, are overexpressed or overproduced in cancer cells (such as those in breast, lung, and ovarian cancers) and have been analyzed in experimental and some human studies as targets for cancer therapy (Figure 1). The gene discussed is SLC2A1; the disease is cancer.